Medicenna to present topline Phase 1/2 ABILITY-1 data for MDNA11 at SITC 2026

• Medicenna flagged topline Phase 1/2 ABILITY-1 data for MDNA11, set for oral presentation at SITC 2026 on Nov. 7.
• Results have not yet been presented; the readout is positioned as evidence of clinical activity in advanced solid tumors.
• MDNA11 showed activity as a monotherapy, with additional activity reported in combination with Merck’s pembrolizumab.
• Abstract highlights responses in biomarker-selected gastrointestinal cancers, including patients whose disease progressed on prior checkpoint inhibitors.
• Selection for an oral slot among top meeting abstracts raises visibility for MDNA11 ahead of further development decisions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medicenna Therapeutics Corp. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610050900PRIMZONEFULLFEED9839530) on October 05, 2026, and is solely responsible for the information contained therein.